Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
about
Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaRenal cell cancer: overview of the current therapeutic landscape.Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialMechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysisPatient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.Emerging antiangiogenics for renal cancer.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Cost-effectiveness analysis of axitinib through a probabilistic decision model.Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational studyAxitinib: a review in advanced renal cell carcinoma.Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.Clinical management of metastatic kidney cancer: the role of new molecular drugs.Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.MCPIP1 contributes to clear cell renal cell carcinomas development.Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors.Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
P2860
Q27028048-FC762320-18A0-44A0-9FFE-28F7E7777C36Q30248354-854826E0-7A99-4767-AA1A-E5A14F38EEA7Q33712944-50D7463A-25D3-45C6-88F9-4F04F761F747Q33750154-812E4F76-0ECC-4F9A-B4F2-7545F4D5CFE3Q34077272-B661D825-5CB0-47AC-8E57-35A5E2309750Q34661185-DEF80640-8C0C-40D5-996C-47E5E2ADBB92Q35434188-702AD2D9-AE3E-4F69-82B1-AA05EDD15CF6Q35591889-57F4AA6F-8FC6-46D0-887E-FDBCA28E0A77Q35758408-6A4D8DD6-669C-48EF-8029-44F601E8DED1Q37513062-6E90733F-DD8D-4ADE-BE15-543F52FBE300Q38166015-1152EBB7-8646-4B9C-8FEB-2F6D95216F36Q38201503-96F666F9-CD9F-4623-BFD2-04DED4E9B63AQ38469815-EFD29975-05B5-45E0-BEEB-8BC0F063B00CQ38531928-A6B836E2-DE1D-4CDB-916F-FDC88143FD6FQ38612808-52E76A92-5670-48FE-8508-3679BFB0EC12Q38633488-3FA80CA8-0B20-4FF8-9331-5FCBA968188BQ38652566-AD0E123F-B089-4FA4-86CB-AF10C8D23E29Q38686066-0A175A3D-9C00-450C-B5A9-5DFC22D239C1Q38754614-DBC84FCD-3C34-45E8-AB03-94DFE693C8CBQ41022521-2D242156-4819-4658-AA98-8E6E6FE50B52Q41756947-DBE74BF4-10A0-4B76-A66F-C086994C66CEQ42921489-E5B9CF75-6F02-41E5-9252-3BE5466129DEQ47616622-17A8F3CF-A9B1-4824-A6B0-BDE625C0C7A3Q48067491-DA22E496-5271-42D5-B19B-885D587A3F65Q52682465-D54189AC-8142-43A2-8712-1112FA37F83E
P2860
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Patient-reported outcomes for ...... inoma: phase III (AXIS) trial.
@en
type
label
Patient-reported outcomes for ...... inoma: phase III (AXIS) trial.
@en
prefLabel
Patient-reported outcomes for ...... inoma: phase III (AXIS) trial.
@en
P2093
P2860
P356
P1476
Patient-reported outcomes for ...... inoma: phase III (AXIS) trial.
@en
P2093
B Escudier
B Rosbrook
H Bhattacharyya
P2860
P2888
P304
P356
10.1038/BJC.2013.145
P407
P577
2013-04-11T00:00:00Z
P5875
P6179
1045286767